1.
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
by Van Gaal, Luc F
The Lancet (British edition), 2005, Vol.365 (9468), p.1389-1397
2.
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
by Scheen, André J
The Lancet (British edition), 2006, Vol.368 (9548), p.1660-1672
3.
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phas...
by Moreno, Carol
The lancet oncology, 2019, Vol.20 (1), p.43-56
4.
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
by O'Brien, Susan, Prof
The lancet oncology, 2014, Vol.15 (1), p.48-58
5.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
by Dreyling, Martin, Prof Dr
The Lancet (British edition), 2016, Vol.387 (10020), p.770-778
6.
Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study
by Camidge, D Ross, Dr
The lancet oncology, 2012, Vol.13 (10), p.1011-1019
7.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
by Hong, David S
The lancet oncology, 2020, Vol.21 (4), p.531-540
8.
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
by Mossé, Yael P, Dr
The lancet oncology, 2013, Vol.14 (6), p.472-480
9.
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants ( Dabigatran , Rivaroxaban , Apixaban ) Versus Warfarin in Patients With Atrial Fibrillation
by Miller, Corey S., BA
The American journal of cardiology, 2012, Vol.110 (3), p.453-460
10.
Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-la...
by Shaw, Alice T, Dr
The lancet oncology, 2017, Vol.18 (7), p.874-886
11.
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
by Lassen, Michael Rud, Dr
The Lancet (British edition), 2010, Vol.375 (9717), p.807-815
12.
Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
by Shaw, Alice T, Dr
The lancet oncology, 2016, Vol.17 (2), p.234-242
13.
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial
by Grainger, John D, Dr
The Lancet (British edition), 2015, Vol.386 (10004), p.1649-1658
14.
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymp...
by Younes, Anas, Prof
The lancet oncology, 2014, Vol.15 (9), p.1019-1026
15.
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
by Hijazi, Ziad, Dr
The Lancet (British edition), 2016, Vol.387 (10035), p.2302-2311
16.
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK -rearranged non-small-cell lung cancer (AF-002JG): results...
by Gadgeel, Shirish M, MD
The lancet oncology, 2014, Vol.15 (10), p.1119-1128
17.
A guide to immunotherapy for COVID-19
by van de Veerdonk, Frank L
Nature medicine, 2022, Vol.28 (1), p.39-50
18.
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
by Padwal, Raj S, Dr
The Lancet (British edition), 2007, Vol.369 (9555), p.71-77
19.
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
by O'Brien, Susan, Prof
The lancet oncology, 2016, Vol.17 (10), p.1409-1418
20.
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
by Lovly, Christine M
Nature medicine, 2014, Vol.20 (9), p.1027-1034
